Instituto de Investigaciones Aplicadas a la Neurociencia A.C. | Durango, Mexico

Research site

(Unclaimed)

Location

Pasteur 205, Zona Centro, Durango, Durango, Mexico

Site insights

Top conditions

Top treatments

Vedolizumab

Ontamalimab

Mirikizumab

Lurasidone

MNK-1411

Ritlecitinib

Fingolimod

Ocrelizumab

Losartan

Baricitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 28 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Active, not recruiting

Stable Nonsegmental Vitiligo

Active Nonsegmental Vitiligo

Drug: Ritlecitinib

Drug: Placebo

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS)

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatiti...

Active, not recruiting

Atopic Dermatitis

Drug: Topical corticosteroid

Drug: Baricitinib

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) (Operetta 2)

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting

Relapsing-Remitting Multiple Sclerosis

Drug: Ocrelizumab

Drug: Fingolimod

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) (SMART)

This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experien...

Active, not recruiting

RSV Infection

Biological: Placebo

Biological: Palivizumab

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with...

Enrolling

Obesity or Overweight

Ulcerative Colitis

Drug: Mirikizumab

Drug: Placebo

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD)

The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administ...

Enrolling

Obesity or Overweight

Crohn's Disease

Drug: Placebo

Drug: Tirzepatide

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo